布里斯托尔·迈尔斯·斯基布(Bristol Myers Squibbb)在Q3 2023中比照收入估计数,报告收入为1.63 EPS和12.22B美元。 Bristol Myers Squibb beat earnings estimates in Q3 2023, reporting $1.63 EPS and $12.22B in revenue.

Bristol Myers Squibb报告说,10月30日Q3收入丰厚,比估计数高出1.63 EPS-0.11美元,收入122.2亿美元,同比增长2.8%。 Bristol Myers Squibb reported strong Q3 earnings on October 30, posting $1.63 EPS—$0.11 above estimates—and $12.22 billion in revenue, up 2.8% year-over-year. 股票交易超过其50天和200天移动平均数,出现机构活动,包括Gamma AS部门增加43.2%的股份和Resona资产管理公司销售。 The stock, trading above its 50-day and 200-day moving averages, saw institutional activity including a 43.2% stake increase by Sector Gamma AS and a sale by Resona Asset Management. 最近与Janux治疗技术公司、微软公司的伙伴关系以及中国间皮瘤试验的进展增强了投资者的信心。 Recent partnerships with Janux Therapeutics, Microsoft, and progress in a China mesothelioma trial bolstered investor confidence. 尽管分析师的看法不一,但7个买,12个持有,1个卖出的看法仍然持有,目标为56.86美元. Despite mixed analyst sentiment—seven Buy, twelve Hold, one Sell—consensus remains Hold with a $56.86 target. 该公司维持1 117亿美元的市场上限,P/E为18.45,76.41%的机构所有权。 The company maintains a $111.17 billion market cap, P/E of 18.45, and 76.41% institutional ownership.